Peficitinib

Peficitinib
Clinical data
Trade names	Smyraf
Other names	ASP015K; JNJ-54781532
ATC code	L04AF06 ( WHO );
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name 4-[((1S,3R)-5-hydroxy-2-adamantyl)amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide;
CAS Number	944118-01-8 ;
PubChem CID	57928403 ;
UNII	HPH1166CKX ;
KEGG	D10721 ;
Chemical and physical data
Formula	C18H22N4O2
Molar mass	326.400 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES NC(=O)c1cnc2[nH]ccc2c1NC1[C@H]2CC3C[C@@H]1CC(O)(C3)C2;
	InChI InChI=1S/C18H22N4O2/c19-16(23)13-8-21-17-12(1-2-20-17)15(13)22-14-10-3-9-4-11(14)7-18(24,5-9)6-10/h1-2,8-11,14,24H,3-7H2,(H2,19,23)(H2,20,21,22)/t9?,10-,11+,1 ; Key:DREIJXJRTLTGJC-JQCLMNFQSA-N ;

Last updated August 24, 2025

Peficitinib (brand name Smyraf) is a pharmaceutical drug used for the treatment of rheumatoid arthritis. It belongs to the class of drugs known as Janus kinase inhibitors (JAK inhibitors).^[1]^[2]

Peficitinib was approved for use in Japan in 2019.^[3]

References

↑ Kivitz AJ, Gutierrez-Ureña SR, Poiley J, Genovese MC, Kristy R, Shay K, et al. (April 2017). "Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate". Arthritis & Rheumatology. 69 (4): 709–719. doi: 10.1002/art.39955 . PMID 27748083.
↑ Genovese MC, Greenwald M, Codding C, Zubrzycka-Sienkiewicz A, Kivitz AJ, Wang A, et al. (May 2017). "Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis". Arthritis & Rheumatology. 69 (5): 932–942. doi: 10.1002/art.40054 . PMID 28118538.
↑ Markham A, Keam SJ (June 2019). "Peficitinib: First Global Approval". Drugs. 79 (8): 887–891. doi:10.1007/s40265-019-01131-y. PMID 31093950. S2CID 155093525.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Kivitz AJ, Gutierrez-Ureña SR, Poiley J, Genovese MC, Kristy R, Shay K, et al. (April 2017). "Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate". Arthritis & Rheumatology. 69 (4): 709–719. doi: 10.1002/art.39955 . PMID 27748083.

[2] Genovese MC, Greenwald M, Codding C, Zubrzycka-Sienkiewicz A, Kivitz AJ, Wang A, et al. (May 2017). "Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis". Arthritis & Rheumatology. 69 (5): 932–942. doi: 10.1002/art.40054 . PMID 28118538.

[3] Markham A, Keam SJ (June 2019). "Peficitinib: First Global Approval". Drugs. 79 (8): 887–891. doi:10.1007/s40265-019-01131-y. PMID 31093950. S2CID 155093525.

[1]

[2]

[3]